To clarify the mechanism of liver damage induced by hepatitis C virus (HCV) and to determine whether the damage is related to hepatocellular carcinoma (HCC), HCV RNA levels were measured serially, and HCV genome mutations were analyzed from serum of 274 Japanese patients with chronic HCV viremia during 1993-1998. All patients had alanine aminotransferase (ALT) levels measured during 1986-1998. Patients with consistently normal ALT levels had identical and highly conserved HCV core regions; however, those with consistently abnormal ALT levels had quasi species, and the population of the quasi species changed over time. HCV RNA levels did not change in the 274 patients. HCC developed in 31% of 80 patients with consistently abnormal ALT levels and in 4% of 92 patients with intermittently abnormal ALT levels but never in 102 patients with ALT levels consistently normal during 1993-1998. In patients with chronic HCV viremia, persistent liver damage plays an important role in the development of HCC.
Since its discovery in 1989, hepatitis C virus (HCV) has been shown to be the causative agent of most cases of parenteral non-A, non-B hepatitis [1] . In patients with chronic HCV infection, especially those who have chronic active hepatitis with cirrhosis, the virus has been directly linked to the development of hepatocellular carcinoma (HCC) [2] . Widespread use of serologic HCV screening tests has led to the identification of many persons among the general population, including blood donors, who have normal serum aminotransferase levels yet are chronically infected with HCV [3, 4] . Interferon is prescribed for patients with chronic hepatitis C, but the use of interferon treatment for HCV-infected patients with normal liver enzyme levels is controversial.
The mechanism involved in liver damage induced by HCV is not well understood. It has been suggested that HCV has a direct cytopathic effect on the liver [5] [6] [7] . Accelerated viral replication may play an important role in liver damage and in the progression of liver disease in patients with chronic HCV infection [5] . However, it is now widely accepted that immune mechanisms are predominant in the pathogenesis of HCVinduced liver damage. Studies concerning the relevance of im-mune-mediated liver damage in patients with HCV infection indicate that cellular immunity against intracellular pathogens, such as viruses, is mainly represented by CD8 cytotoxic T lymphocytes (CTLs) [8, 9] . In chronic HCV infection, various quasi species of virus can coexist, eliciting a multispecific CTL response. Quasi species in the core region were found in HCVinfected patients with abnormal liver enzymes but not in those with normal liver enzymes [10] .
Because most previous studies, including ours, had used cross-sectional surveys that may have yielded biased results, we performed a longitudinal cohort study to resolve questions concerning the role played by viral properties in the liver damage associated with chronic HCV infection. Previously, we had studied persons from a rural area of Japan where HCV infection is common [3] and where serial testing for serum alanine aminotransferase (ALT) had been done routinely since 1986 [10] . To clarify the natural history of HCV-related disease and the relationship between viral properties and liver damage in a cohort of patients in this village, we serially measured HCV RNA levels and analyzed mutations in the putative core region of the HCV genome.
Methods
Study population. The public office of village H in Fukuoka Prefecture, Japan, provides free yearly health examinations, announced by distributing written notices to residents у30 years old. Fukuoka Prefecture is located in the northwest part of Kyushu Island, one of the main islands of Japan. Village H is surrounded by mountains and is relatively isolated from other communities. According to the records of the village office, the population of this village was 4250 in 1993 [3] . Liver biochemical tests (determinations of levels of ALT, aspartate aminotransferase, and g-glutamyl [3, 10] . Results of biochemical liver tests were considered abnormal if the ALT level was 136 IU/L. Patient who were positive for HCV RNA at least twice, at an interval of у1 year, were classified as having chronic HCV viremia. After excluding patients who were also positive for hepatitis B surface antigen, we analyzed results in a study population of 274 patients who had chronic HCV viremia and abnormal ALT levels (148 men, 126 women; ages 43-82). These individuals underwent examinations 3 or 4 times each year during 1993-1998.
Serial determinations of HCV markers and serum ALT and afetoprotein levels, as well as abdominal ultrasonography, were performed in study patients once a year between 1994 and 1998. When HCC was detected at other clinical facilities, patient data were transferred to our laboratory. No study patient had been treated with antiviral agents, such as interferon, or with immunosuppressants, such as steroids.
The 274 patients were categorized into 3 groups according to the number of times serum ALT levels were elevated during 1986-1992. Group A comprised 102 patients (37%) whose levels were always normal; group B comprised 92 patients (34%) with levels that were intermittently abnormal; and group C comprised 80 patients (29%) whose levels were always abnormal (table 1) . The percentage of men in group C (71%) was significantly higher than in group A (37%; ) or group B (58%; ). The P ! .001 P ! .01 mean (‫ע‬SD) ages were not significantly different among the 3 groups:
years in group A, years in group 63.3 ‫ע‬ 10.5 61.7 ‫ע‬ 9.5 B, and years in group C. HCV RNA of genotype 1b 61.4 ‫ע‬ 9.2 was found in 245 patients (89%), genotype 2a in 27 (10%), and genotype 2b in 2 (1%). The 1b genotype was the most prevalent in each group.
Assay methods. All serum samples collected during 1993-1998 were separated and stored at Ϫ20ЊC until testing. Samples were assayed to detect antibody to HCV, to detect HCV RNA by use of polymerase chain reaction (PCR), to determine the HCV RNA genotype, and to measure HCV RNA levels. Antibody to HCV was measured by ELISA (HCVEIA II; Abbott Laboratories, Abbott Park, IL). The presence of hepatitis B surface antigen was determined by commercial serologic tests.
HCV RNA determination by PCR. RNA was extracted from 50 mL of serum by Sepa Gene RV (Sanko Junyaku, Tokyo). cDNA was synthesized by use of random primers and reverse transcriptase (Super Script II; Life Technologies, Gaithersburg, MD). HCV RNA was detected by 2-stage PCR with primers from the 5 -noncoding region of the HCV genome [11] : 5 -CTGTGAGGAACT-ACTGTCTT-3 (sense) and 5 -AACACTACTCGGCTAGCAGT-3 (antisense) in the first stage and 5 -TTCACGCAGAAAGCGAC-TAG-3 (sense) and 5 -GTTGATCCAAGAAAGGACCC-3 (antisense) in the second stage.
HCV RNA genotype. The HCV RNA genotype was determined by 2-stage PCR with universal and type-specific primers from the putative C gene of the HCV genome, by a modification of the method of Okamoto et al. [12] . The genotype nomenclature was based on the system proposed by Simmonds et al. [13] .
Quantitative detection of serum HCV RNA. HCV RNA levels of patients with chronic HCV infection were determined by use of a second-generation branched DNA signal-amplification method (Quantiplex HCV RNA; Chiron, Emeryville, CA). The range of linear relationship provided by the branched DNA assay was 0.2- [14] . 6 57 ϫ 10 For semiquantitation, HCV RNA extracted from the serum of HCV carriers was serially diluted 10-fold with distilled water free of RNase. It was supplemented with 40 mg/mL poly(A), converted to cDNA, and then amplified by PCR with nested primers. The primers were from the 5 -noncoding and core regions of the HCV genome. The highest dilution positive for HCV RNA was determined, from which the HCV RNA level in 50 mL of serum (10 n / 50 mL) was estimated.
Sequencing. We selected 17 patients with chronic HCV viremia for serial sequence analysis of the HCV core region (aa 57-126). All patients had HCV RNA genotype 1b and HCV RNA levels of 10 5 -10 6 copies/50 mL. Genotypes were determined by use of PCR with primers from each region, to avoid the bias of viral properties, from serum samples of sufficient volume for serial sequencing. Fragments of cDNA were subcloned into pT7Blue T vectors (Novagen, Madison, WI) . Twenty independent clones of the target size were isolated from each serum sample and were sequenced by use of the dideoxynucleotide method with an ABI automated sequencer (Applied Biosystems, Foster City, CA). Duplicate PCR amplifications were done from multiple independent first-strand cDNA mixtures.
Statistical analysis. Data were analyzed by x 2 test, KruskalWallis 1-way analysis of variance, Mann-Whitney U test, and the log rank test.
was considered statistically significant. P ! .05 , group A vs. group B; , group A vs. P ! .05 P ! .001 group C; and , group B vs. group C. P ! .001 in group A, the group whose ALT levels were always normal during 1986-1993, ALT levels became abnormal (always or intermittently) during 1994-1998 in a total of 15 patients (15%), and levels were always normal during 1984-1998 in the remaining 87 (85%). In group B, 50 patients (54%) had intermittently abnormal ALT levels throughout 1986-1998, and 28 (31%) always had abnormal levels during 1994-1998. In the remaining 14 patients (15%), ALT levels were always normal during 1994-1998. In group C, 77 patients (96%) had consistently abnormal ALT levels during 1986-1998, and 3 (4%) had intermittently abnormal levels during 1994-1998.
Results

Biochemical
Virologic outcomes. Serum HCV RNA levels in 1993 and 1998 among the 274 patients with chronic HCV viremia are shown in figure 1 . In groups A and C, HCV RNA levels did not significantly change in any patient and were not related to changes in serum ALT levels. In group B, serum HCV RNA levels significantly increased in the 14 patients whose serum ALT levels were normal during 1994-1998. Among the remaining 78 patients, the HCV RNA levels did not significantly change. No patient with chronic HCV viremia eliminated HCV RNA from serum within the 5-year period of the present study.
Development of HCC. HCC was found in 29 (11%; 20 men, 9 women; 58-80 years old) of the 274 patients with chronic HCV viremia in the 5-year study period: 27 (11%) of 245 patients with genotype 1b and 2 (7%) of 27 with genotype 2a. Among the 92 group B patients, 4 cases of HCC (4%) were detected during the 5 years, as were 25 cases (31%) among 80 group C patients. The annual HCC incidence in group C was 6%. However, no HCC was found among the 102 patients of group A. HCC incidence was significantly higher in group C than in group A or B (
). The cumulative incidence of P ! .001 HCC in patients with chronic HCV viremia was significantly different among the 3 groups ( , log rank test; figure 2 ). P ! .001 The overall incidence of HCC was 14% in men and 7% in women, but among the 80 patients in group C, the incidence was 28% in men and 39% in women; the differences between the sexes were not significant.
Sequence changes in the core region. We selected 17 patients with chronic HCV viremia for serial sequence analysis of the HCV core region (aa 57-126; table 2). All patients had HCV RNA genotype 1b and HCV RNA levels of 10 5 -10 6 copies/50 mL, determined by end-point dilution assay. A consensus sequence for each patient was calculated from 20 deduced amino acid sequences, which were then compared. Of the 17 patients, 5 (patients 1-5) had normal ALT levels throughout the observation, and the deduced amino acid sequences were identical, with no change in any patient between 1993 and 1998. Five other patients (patients 6-10) had normal ALT levels during 1986-1993 but abnormal levels during 1994-1998. The deduced amino acid sequences were identical in each patient in 1993, but there were differences in the sequences of the 20 clones from each patient in 1998. The remaining 7 patients (patients 11-17), 3 of whom developed HCC between 1994 and 1998 (patients [15] [16] [17] , had abnormal ALT levels throughout the observation. The number of main clones decreased, and the number of quasi species increased in all of these patients during 1994-1998. Figure 3 shows the clinical course of 4 patients with chronic HCV viremia and the results of serial sequence analysis of the HCV core region of each of the 20 clones. Patient 1, who had consistently normal ALT levels during 1986-1998, had highly conserved HCV core regions (only clone A) in 1993, 1995, and 1998. Patient 6, who had normal ALT levels during 1986-1993 and abnormal levels during 1994-1998, had only clone A and no quasi species in the HCV core region in 1993. However, in 1995, the number of type A clones decreased from 20 to 12, and other clones-B, C, and D-were found in the core region. In 1998, the number of type A clones decreased to 8, and clones E and F were found. Thus, in patient 6, the number of species increased to 4 among the 20 clones in 1995 and to 6 in 1998. Patient 11, who had consistently abnormal ALT levels during 1986-1998, had 3 species (clones A, B, and C) among the 20 clones detected in 1993 but also had clones D and E in 1998. Patient 16, who had consistently abnormal ALT levels during 1986-1998, had 3 species among the 20 clones in 1993; however, 5 species had evolved when HCC developed in 1997.
Discussion
This large-scale, combined retrospective and prospective study revealed that some patients who had chronic HCV viremia with consistently normal liver enzymes for a decade had elevations in ALT levels. This is consistent with observations that blood donors with HCV RNA show signs of chronic hepatitis in liver biopsy specimens, despite normal ALT levels [7] . Hagiwara et al. [5] and Gordon et al. [15] reported that the HCV RNA level was high in patients with advanced liver disease. However, we found that the HCV RNA level varied independently of the stage of liver disease or the serum ALT level [16, 17] , a finding recently supported by other investigators [18, 19] . The present finding that the HCV RNA levels did not significantly change in cohorts of patients who had normal liver enzyme levels during 1986-1993 but had abnormal enzyme levels during 1994-1998 confirmed that HCV RNA level is not related to liver damage. Another striking finding is that no patient eliminated HCV RNA from serum within the 5 years. HCV probably is seldom eliminated naturally in patients with chronic viremia, in contrast to hepatitis B virus [20] .
The most interesting finding of our study was that the deduced amino acid sequences in the HCV core region of patients with consistently normal liver enzyme levels were identical and remained unchanged over a 5-year period. However, in patients with consistently abnormal liver enzyme levels, HCV quasi species persisted, and the population of the quasi species changed over time. Kurosaki et al. [21] , who used PCR single-strand conformation polymorphism analysis, found that sequential variations in the core region were more pronounced in patients with high ALT levels than in those with low levels. These results indicate that the development of quasi species in the HCV core region is related to liver damage, because the core region analyzed in the present study is highly immunogenic and is recognized by CTLs [22] . Development of a CTL response depends on the genetic makeup of the host. If a strong CTL response occurs, it will increase the amount of cell damage and the opportunity to select CTL-resistant variants, which are reflected as quasi species. In chronic HCV infection, extensive quasi species of virus variants can coexist, eliciting a multispecific CTL response. CTL escape has been observed in a chronically HCVinfected chimpanzee [23] .
It was reported that the annual incidence of HCC was 3%-4% in patients with chronic liver disease and chronic HCV infection [24] [25] [26] . The frequency of HCC was significantly higher in patie nts with cirrhosis than in those with chronic hepatitis [25, 27] . Although the liver histology of our patients was not examined by needle biopsy, it is clear that HCC is an outcome of longterm liver damage in patients with chronic HCV viremia. However, there were no occurrences of HCC in patients with consistently normal liver enzyme levels over a long period of time. Cell damage leads to regeneration of liver cells, which in turn can result in carcinogenesis. Moreover, our results indicate persuasively that HCV infection is not directly carcinogenic.
Because patients with HCV RNA seldom naturally seroconvert from positive to negative, interferon treatment is required in patients with liver damage, both for the elimination of HCV RNA [5, 28] and to reduce the incidence of HCC [24] . Conversely, interferon treatment is not required for patients with normal liver enzyme levels, especially for those with no quasi species.
Women seem to eliminate HCV more easily than men; HCV RNA positivity in anti-HCV-positive subjects was significantly more frequent in men than in women [3] . Similarly, among patients with chronic HCV infection, liver biochemical test results were less frequently abnormal in women than in men [10] . However, there was no difference between the sexes in the incidence of HCC, especially among patients with abnormal liver enzymes. Although HCV appears to affect women less frequently than it does men, the progression of liver damage, after the initiation of hepatitis, may not differ between the sexes.
In conclusion, persistent liver inflammation plays an important role in the development of HCC in patients with chronic HCV viremia. HCV itself is not intrinsically carcinogenic.
